Shire PLC (SHP) Given Buy Rating at Citigroup Inc.
A number of other analysts also recently weighed in on the company. Royal Bank Of Canada restated an outperform rating on shares of Shire PLC in a report on Wednesday, June 15th. JPMorgan Chase & Co. restated an overweight rating and issued a GBX 6,300 ($82.23) price objective (up from GBX 5,600 ($73.10)) on shares of Shire PLC in a report on Monday, August 1st. Jefferies Group increased their price objective on Shire PLC from GBX 6,050 ($78.97) to GBX 6,600 ($86.15) and gave the company a buy rating in a report on Wednesday, August 3rd. Morgan Stanley restated an overweight rating and issued a GBX 5,600 ($73.10) price objective on shares of Shire PLC in a report on Friday, June 3rd. Finally, BNP Paribas restated an outperform rating and issued a GBX 5,700 ($74.40) price objective on shares of Shire PLC in a report on Monday, June 6th. One research analyst has rated the stock with a sell rating, one has issued a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Shire PLC currently has an average rating of Buy and a consensus price target of GBX 5,841.33 ($76.25).
Shares of Shire PLC (LON:SHP) opened at 5278.00 on Monday. Shire PLC has a 1-year low of GBX 2,707.19 and a 1-year high of GBX 5,300.00. The firm’s market cap is GBX 36.04 billion. The firm has a 50 day moving average price of GBX 4,955.75 and a 200 day moving average price of GBX 4,434.49.
The firm also recently declared a dividend, which will be paid on Friday, October 7th. Investors of record on Thursday, September 8th will be given a GBX 3.51 ($0.05) dividend. The ex-dividend date is Thursday, September 8th. This represents a yield of 0.07%.
In other Shire PLC news, insider Bohuon,Olivier purchased 134 shares of the company’s stock in a transaction that occurred on Thursday, June 30th. The shares were acquired at an average price of GBX 4,463 ($58.26) per share, with a total value of £5,980.42 ($7,806.32).
About Shire PLC
Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines.
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.